Observational studyFrontiers in endocrinology2025
The role of SHR in risk stratification for long-term prognosis in patients with coronary artery disease: findings from a large cohort study.
Observational study in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between stress hyperglycemia ratio and acute total occlusion in patients with non-ST-segment elevation myocardial infarction.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recently, the Stress Hyperglycemia Ratio (SHR) - which integrates acute increases in blood glucose with long-term glycemic control levels - has shown independent predictive value for adverse events in patients with acute coronary syndrome (ACS). However, the long-term prognostic significance of SHR in a broader population of coronary artery disease (CAD) remains unclear. This study aimed to explore the role of SHR in prediction of long-term prognosis of CAD. Methods: In this cohort study, we enrolled 23,591 participants diagnosed with CAD from January, 2016, to December, 2021 in Beijing Hospital. After excluding patients lacking data, with cancers, or missing follow-ups, 7,162 patients were finally enrolled into the analyses. The SHR was calculated using the following equation: SHR = admission glucose (mmol/L)/(1.59 × HbA1c [%]-2.59). The 7,162 participants were divided into three groups based on SHR tertiles: Tertile 1 (SHR ≤ 0.72, n=2391), Tertile 2 (0.73≤SHR ≤ 0.82, n=2388), and Tertile 3 group (SHR≥0.83, n=2383). The primary endpoint was all-cause mortality and cardiovascular death (CVD), while the second endpoint was major adverse cardiovascular events (MACE). The median follow-up was 28 months. Results: Our results suggest that SHR was significantly associated with increased risks of long-term all-cause death, CVD death, and MACE. The Kaplan-Meier curves revealed that the highest tertile (T3) group had the highest risk of all-cause death, CVD death, and MACE, while the lowest tertile (T1) group had the lowest risk (all log-rank P < 0.05). After adjusting risk factors, the results of cox regression analyses showed that SHR was significantly associated with all three outcomes (all P < 0.05). For all-cause death, SHR was associated with an increased risk of all-cause death in the fully adjusted model (Model 3: HR = 2.52, 95% CI: 1.57 - 4.05, P < 0.001). Compared to the lowest tertile (T1), participants in the highest tertile (T3) had a likely higher risk of all-cause death (HR = 1.40, 95% CI: 1.05 - 1.87, P = 0.021). SHR also demonstrated a positive association with CVD death (Model 3: HR = 2.87, 95% CI: 1.22 - 6.76, P = 0.016), and participants in T3 had a significantly higher risk of CVD death compared to T1 (HR = 1.94, 95% CI: 1.11 - 3.40, P = 0.021). Additionally, SHR was also independently associated with MACE (Model 3: HR = 1.70, 95% CI: 1.21 - 2.38, P = 0.002). The risk of MACE was significantly higher in T3 compared to T1 (HR = 1.21, 95% CI: 1.02 - 1.45, P = 0.031). The restricted cubic spline (RCS) analysis further confirmed a positive nonlinear association between SHR and these adverse outcomes (all-cause death, CVD death, and MACE) and exhibited a J-shaped curve. Conclusions: SHR is significantly associated with long-term all-cause death, CVD death, and MACE in CAD patients. Our findings highlight SHR can be used as a valuable tool for long-term prognosis risk stratification in CAD, potentially influencing clinical decision-making and patient management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.